The fund-raising values the company at $3.8 billion and underscores investor interest in using artificial intelligence to tackle problems like drug discovery.
For many inside and outside Silicon Valley, artificial intelligence development means working on giant all-purpose tools like Anthropic’s Claude and OpenAI’s GPT family of models.
But investors continue to pour money into more specialized application... [1293 chars]